echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > FDA approves nuclide conjugate drugs for prostate cancer diagnosis!

    FDA approves nuclide conjugate drugs for prostate cancer diagnosis!

    • Last Update: 2021-12-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On December 20th, Telix Pharmaceuticals announced that the FDA approved Illuccix (TLX591-CDx) for the marketing of prostate cancer diagnostic imaging


    TLX591-CDx is a diagnostic positron emission tomography (PET) tracer targeting prostate specific membrane antigen (PSMA) based on radionuclide-antibody coupling technology (RDC), suitable for metastatic prostate cancer And the diagnosis of recurrent prostate cancer


    The National Comprehensive Cancer Network (National Comprehensive Cancer Network) prostate cancer guidelines (2020 edition) recommends TLX591-CDx as a new PET tracer.


    In November 2020, Grand Pharmaceuticals signed a cooperation agreement with Telix, and obtained a number of first in class tumor diagnostics (TLX250-CDx, TLX599-CDx) and treatments (TLX591, TLX250, TLX101), including TLX591-CDx, in one fell swoop The exclusive commercialization rights of global innovative RDC products in Greater China (including Hong Kong, Macau, Taiwan), and the company with the largest number of therapeutic + diagnostic RDC drugs in China


    Prostate cancer is one of the most common male cancers.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.